CARVYKTI demonstrated a 45% reduction in the risk of death compared to standard therapies in multiple myeloma patients.

Kostas Biliouris’s rating is based on several compelling factors that highlight Legend Biotech’s strong market position and future potential. The increasing uptake of Carvykti, driven by its ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Legend Biotech Corporation (NASDAQ ... In the third quarter, we are pleased that CARVYKTI cells continued their strong ...

Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech reports third quarter 2024 financial results. (Operator Instructions) Please be advised that today's conference is being ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Legend Biotech has established itself as a key player in the multiple myeloma (MM) treatment space, primarily due to the success of Carvykti. This chimeric antigen receptor T-cell (CAR-T ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the ...

SOMERSET, N.J. - Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company specializing in cell therapy, announced Monday the appointment of Alan Bash as the President of CARVYKTI, a ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Legend Biotech Corp (NASDAQ:LEGN), a biopharmaceutical company specializing in novel cell therapies for oncology, has been making waves in the healthcare sector with its flagship product, Carvykti. As ...